Mineralys Therapeutics MLYS
Mineralys Therapeutics, Inc. · Nasdaq · Pharmaceutical Preparations
$21.38+1.18%close on Oct. 28, 2026 · volume 1.5M · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 30, 2026 | Jon Congleton Chief Executive Officer, director | Sold 10b5-1 plan | 75,000 | $25.46 | $1.91 million |
| Sept. 22, 2026 | Brian Taylor Slingsby director · indirect | Sold | 104,320 | $28.81 | $3.01 million |
| Sept. 21, 2026 | Eric Warren Chief Commercial Officer | Sold 10b5-1 plan | 7,438 | $28.12 | $209,136 |
| Sept. 15, 2026 | Daphne Karydas director | Sold 10b5-1 plan | 3,000 | $28.58 | $85,740 |
| Aug. 21, 2026 | Eric Warren Chief Commercial Officer | Sold 10b5-1 plan | 7,437 | $25.98 | $193,189 |
| Aug. 10, 2026 | David Malcom Rodman Chief Medical Officer | Sold 10b5-1 plan | 2,170 | $27.09 | $58,785 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 13 →Departure/appointment of directors or officers · Financial statements and exhibits
AI summary, unreviewedMineralys Therapeutics Adds Two Independent Directors, Expanding Board From Seven to Nine